Matica Biotechnology, Inc. demonstrated a microfluidic clarification system for lentiviral vector harvest achieving greater than 95% vector recovery and greater than 95% cell removal while avoiding product losses commonly associated with depth filtration.
Published
Signal category
Research & Knowledge
Quote
“Researchers demonstrated a microfluidic clarification system for LVV harvest that achieved greater than 95% vector recovery and greater than 95% cell removal while avoiding the product losses commonly associated with depth filtration.”
— John Childers|Matica Biotechnology, Inc. team
Company
Matica Biotechnology, Inc.
Your CDMO for gene therapy and viral vectors
- Industry
- Biotechnology Research
- Location
- College Station, US
- Company size
- 69 employees
Matica Biotechnology, Inc. is a contract development and manufacturing organization (CDMO) specializing in the production of viral vectors and gene therapies. Our exceptional team of industry veterans, with over 15 years of experience, has a proven track record in delivering innovative products to the clinic and market. At Matica Bio, our mission is to provide a streamlined, global manufacturing solution for our clients' products. Our state-of-the-art single-use bioreactor platforms, remote monitoring systems, quality-driven processes, and dedicated staff work together seamlessly to ensure a reliable and efficient product development and manufacturing process. Our unwavering focus on quality, compliance, and patient safety allows us to meet the often-accelerated clinical approval pathways, getting our clients' products to the patient bedside quickly and efficiently. Trust Matica Bio to be your partner in advancing healthcare through advanced therapies.
Founded 2019